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Abstract
Background: Ten cancer patients (Six renal cell carcinoma and four breast cancer patients) were treated in a phase
I/II study with a vaccine composed of autologous dendritic cells (DCs) and IL-2 to evaluate the DC vaccine-related
toxicity and antigen-specific immune alteration.
Methods: Cancer patients were treated twice with autologous CD34
+ hematopoietic stem cell-derived, GM-CSF/
IFN-g-differentiated DCs pulsed with autologous tumor lysate and KLH, by 4-week interval. Following each
subcutaneous injection of therapeutic DCs, low-dose (200 MIU) IL-2 was introduced for 14 consecutive days as an
immune adjuvant. To determine the DC vaccine-induced immunological alterations, the KLH-specific lymphocyte
proliferation, number of IFN-g secreting T cells (ELISPOT assay), NK activity and the cytokine modulation were
measured.
Results: Cultured-DCs expressing HLA-DR, CD11c, CD83, and B7.1/B7.2 produced IL-12p70. After vaccination, the
patients tolerated it. Clinical response was observed in one RCC patient as stable disease. However DC-vaccine
related antigen-specific immune responses including peripheral blood lymphocyte proliferation and the number of
IFN-r secreting cells were induced in six patients without clear correlation with clinical responses. Also NK activity
was induced significantly in six patients after vaccination. DC vaccine-related decrease of TGF-b level or increase of
IL-12p70 level and decline of CD4
+CD25
+ T cells were observed in three patients. However only in the RCC patient
whose disease stabilized, combination of stimulatory as well as inhibitory immune alterations including induction
of IFN-g secreting T cell with reduction of CD4
+ CD25
+ T cell were correlated with clinical responses.
Conclusion: Data indicated that DC vaccine combined with IL-2 is well tolerated without major side effects. DC
vaccine induced the specific immunity against introduced antigen. Combinatorial alterations of immunological
parameters indicating antigen-specific immune induction along with reduction of inhibitory immunity were
correlated with clinical responses in DC vaccine treated patients.
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Background
As a professional antigen-presenting cell (APCs), DC
induces antigen specific cytotoxic T lymphocyte (CTL)
response thus DC vaccine has been anticipated as a can-
cer treatment regimen [1,2]. Subsets of therapeutic-DCs
are known to have functional importance. Tumor anti-
gen-specific immunity is induced by myeloid-DCs cul-
tured from peripheral monocytes or hematopoietic stem
cells (HSC). Cultured therapeutic myeloid-DCs induce
not only the antigen-specific effecter T cells (both Th
and CTLs) but also NK cell activity which can help the
induction of anti-tumor responses [3-6]. Reciprocally,
NK cells can activate DCs, enhancing their ability to
produce pro-inflammatory cytokines and stimulate T
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specific CD4
+ and CD8
+ T cells [4,5,7,8].
Renal cell carcinoma (RCC) accounts for 2-3% of all
adult cancers. Although surgery is the primary curative
therapy for patients with localized RCC, the prognosis
for patients with advanced metastatic disease is poor,
with a 5-yr survival rate of < 10% [9]. Because RCC is
one of the most immune responsive cancers in human,
immune- therapy with tumor infiltrating lymphocytes or
lymphokine-activated killer cell has been studied with
considerable side effects [10,11]. More recently, empha-
sis has shifted to the use of DCs to actively immunize
cancer patients with their own DCs loaded with tumor
antigens [12-16]. Unlike RCC, breast cancer is tradition-
ally considered as a poorly immunogenic tumor, there
are evidences for DC recruitment within tumor-micro-
environment. Reports indicated the favorable impacts of
intra-tumoral activated DCs on breast cancer patients’
survival [17-19]. Furthermore, there is a striking paucity
of activated DCs within the primary draining or sentinel
lymph nodes of breast cancers [20,21]. In this study, the
significance of the DC vaccine combined with IL-2 in
renal cell carcinoma and breast cancer patients is pre-
sented regarding the relevance between the clinical and
immunological responses.
Materials and methods
Culture Media and Reagents
Complete medium (CM) including X-VIVO 20 (Bio-
Whittaker, Walkersville, MD, USA) supplemented with
1% human albumin (Green Cross, Seoul, South Korea),
2 mM glutamine, and 100 U/mL penicillin plus 100 μg/
mL streptomycin (Gibco, Grand Island, NY, USA) were
used to culture therapeutic-DCs. Recombinant human
GM-CSF (LG Life Sciences, Seoul, South Korea), IFN-g
(R&D Systems, Minneapolis, MN, USA) were used to
derive DCs. ELISA detection of IFN-g,I L - 1 0 ,a n dI L -
12p70 release in therapeutic-DC culture supernatant
was performed using commercially available ELISA kits
(R&D Systems, Minneapolis, MN, USA). Detection of
IL-10, IL-12, TGF-b and IFN-g release in patient’s
plasma was performed using ELISA kits OptEIA™ (E-
bioscience, San Jose, CA, USA) and Quantikine
® (R&D
Systems Inc., Minneapolis, MN, USA) for VEGF. Key-
hole limpet hemocyanin (KLH; Calbiochem, Germany)
were used adjuvant. K562 is a human leukemia cell line
for NK activity that was purchased from the American
Type Culture Collection (ATCC, Rockville, MD, USA).
Patients’ Criteria
The clinical trial protocol for this study was approved by
the Institutional Review Board of the Asan Medical
Center on 2004. Korean Food and Drug Administration
(KFDA) approved the protocol as an Investigative Trial
on 2004. Patients were informed of the investigative nat-
ure of this study, and written consent in accordance
with institutional regulations was obtained prior to
study entry. Patients with five stage IV and one recur-
rent stage II renal cell carcinoma or stage IIb~IV breast
cancer were enrolled for this study. Patients were
enrolled from Jan. 2005 to Jan. 2007 (Table 1). The
median age was 48 years (range, 24-67 years).
Generation of Therapeutic-DCs
Therapeutic-DC was prepared in the GMP facility at
the FCB-Pharmicell, Korea. To generate hematopoietic
stem cell (HSC)-derived DC, CD34
+ cells were purified
from the washed PBMCs by MACS™ cell separation
system using anti-CD34-coated magnetic beads (Milte-
nyi Biotec, Germany). Enriched CD34
+ cells were
resuspended in CM supplemented with GM-CSF (50
ng/mL), plated at a density of 2~3 × 10
5/cm
2 in 75-
cm
2 flasks. On day 7, culture medium was replaced
with CM containing GM-CSF (50 ng/mL) and IFN-g
(10 ng/mL), and the cells were cultured for another 7
days. On day 13, autologous tumor lysate (30 μg/mL)
and 1 μg/mL of KLH were pulsed to the cells for over-
night. To make tumor lysate, resected tumors were
Table 1 Patient’s characteristics
Pt. # Age
/sex
Stage
/Grade
Diagnosis Metastasis
R-M-1 62/M TxNxM1(IV) Clear cell RCC Lung, Rib
R-G-2 56/M T3bN1M1(IV) Clear cell RCC Lung, Paratracheal LN
R-K-3 67/M T2N0M1(IV) Clear cell RCC Lung, Brain, Contralateral Kidney,
R-H-4 29/M TxN2M0(II) RCC Local Recurrence
R-N-5 24/F T2N2M1(IV) Papillary RCC Lung, Lower Neck, Supraclavicular & Retroperitoneal LN, Local Recurrence
R-L-6 62/M TxNxM1(IV) RCC Thorax, Lung, Mediastinum
B-S-1 43/F IV Lt.breast cancer Breast, Lung
B-H-2 29/F IV Bilateral breast cancer Breast, Lung, skin, pleural
B-L-3 59/F IIIC Brest cancer LN, chest wall, bone meta
B-Y-4 66/F IIB Rt.breast cancer Bone, pleural liver
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freezing in liquid nitrogen and thawing in 37°C water
bath. The tumor lysate was centrifuged, and the super-
natant was filter-sterilized and stored at -80°C until
use. Protein concentrations of the tumor lysate were
determined using BCA Protein Assay Reagent Kit
(Pierce, Rockford, IL, USA).
O nd a y1 4o fc u l t u r e ,t h eD C sw e r eh a r v e s t e d ,
washed, and resuspended to a final concentration of 1 ×
10
7 cells per mL in saline solution for the injection. Cri-
teria for release of clinical grade DCs included viability
greater than 70% and absence of microbial contamina-
tion (bacteria, fungus, and mycoplasma).
Vaccination
Autologous DCs (5 × 10
7/5 mL) were injected subcu-
taneously adjacent to axillary lymph node. Six to ten
hours after DC injection, IL-2 (2 × 10
6 IU; Novartis,
Basel, Switzerland) administration began into an abdo-
men subcutaneously for consecutive 14 days. Patients
were re-vaccinated 4 weeks after the first DC injec-
tion. Responses were analyzed after 2 cycles of DC
vaccine and IL-2 treatment. Immune responses were
evaluated at 0, 4 and 8 weeks of first DC treatment
(Figure 1).
Therapeutic-DC Characterization
Immunophenotypic analysis by flow cytometry
Phenotype of cultured cells was analyzed by direct
immunofluorescence staining of cell surface antigens
using FITC or PE conjugated antibodies against CD1a,
CD40, CD11c, CD80, CD83, CD86, HLA-DR, and the
appropriate isotype matched controls (BD Bioscience
Pharmingen, San Diego, CA, USA). Samples were ana-
lyzed on EPICS XL-MCL flow cytometer (Beckman
Coulter, USA) using Expo32 ADC analysis software.
Cytokine secretion
Culture supernatants from day 7 (GM-CSF) and day 14
(GM-CSF+IFN-g)w e r eo b t a i n e dt om e a s u r et h ec y t o -
kine secreted from the cells. To characterize the type of
differentiated DCs, the level of IL-12 and IL-10 along
with IFN-g was observed by ELISA kit (R&D Systems
Inc., Minneapolis, MN, USA).
Immune Monitoring
NK activity
Lymphocytes from the patient’s peripheral blood served
as effector cells (E). Log-phase K562 cells, a human
chronic myelogenous leukemia cell line sensitive to NK-
cell killing, were labeled with Na2
51CrO4 and used as
target cells (T). Labeled K562 cells (1 × 10
4 cells) and
Figure 1 Vaccination and immune monitoring Protocol.
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or 50:1) were dispensed in a U-bottomed 96-well micro
titer plate. After 4 hour incubation at 37°C in a humidi-
fied 5% CO2 incubator, the supernatant was removed
and the radioactivity levels were assessed in a Wallac
1470 Wizard™ gamma counter (Finland). Spontaneous
release (SR) and total release (TR) were measured in the
supernatants of target cells incubated with either culture
medium or 1N HCL. NK-cell activity was calculated by
following equation;
NKcellactivity(%) = [(experimental cpm − SRcpm) ÷ (TRcpm − SRcpm)] × 100
Phenotype analysis
Fluorescence (either FITC or PE)-tagged antibodies were
incubated with lymphocytes for 40 min at 4°C and the
fluorescence was detected with FACSVINTAGE (Bec-
ton-Dickson, Mountain View, CA) within 2 hrs after
antibody staining. Following antibodies were utilized:
CD16/CD56 for NK cell subsets and CD4/CD25 for the
T cell subset (BD Pharmingen, San Diego, CA, USA).
Mouse IgG1-FITC and mouse IgG2a-RPE (DAKO,
Glostrup, Denmark) were used as negative control.
Lymphocyte proliferation assay
Peripheral blood samples were collected in the heparin
tube before and after 8 weeks of DC vaccination. Lym-
phocytes were separated by density gradient centrifuga-
tion using lymphocyte separation medium
® (Cellgro,
Mediatech, USA). Cells were seeded in triplicates in 96-
well plates (2 × 10
5 cells/well) with KLH (10 μg/ml) at
37°C, in humidified and 5% CO2-conditioned air for 4
days. Cells were loaded with 1 μCi
3H-thymidine/well
(Perkin-Elmer Inc., MA, USA) during the last 18 h of
incubation. Cells were harvested on the glass micro-
fiber filter using a PhD
® cell harvester (Cambridge
Technology Inc., Cambridge, MA, USA). The prolifera-
tive response was determined by
3H-thymidine incor-
poration using a liquid scintillation counter (Beckman
LS 6500; Beckman Instruments Inc., Fullerton, CA,
USA).
Analysis of IFN-g producing cells using ELISPOT assay
The ELISPOT assay was adopted to detect and enumer-
ate individual cells that secrete IFN-g protein in vitro
upon exposure to antigen. ELISPOT assays were per-
formed according to the manufacturer’s instruction
(AID, Strassberg, Germany). In brief, using magnetic
bead cell separation system (MACS™ Miltenyi Biotec,
Germany) CD3
+ T cells were purified from the patient’s
peripheral lymphocytes (2 × 10
5 cells) and stimulated in
vitro with KLH (10 μg/ml) on a 96-well pre-coated
plate. The plate was incubated for 20 h at 37°C with 5%
CO2. After washing, each well was added with detection
antibody and was incubated for 2 h at room tempera-
ture. The plate was incubated with alkaline phosphatase
conjugate and developed with BCIP/NBT substrate solu-
tion. Visible spots were enumerated using an automated
AID ELISPOT reader (AID, Strassberg, Germany) and
the default program.
Measurement of cytokine level
Alterations in blood circulating concentrations of IL-10,
IL-12, TGF-b,V E G Fa n dI F N - g during immunotherapy
were measured by ELISA. Plasma was obtained from the
patient’s peripheral blood before, during, or after treat-
m e n ta n ds t o r e da t- 7 0 ° Cu n t i lt h eE L I S Aw a sp e r -
formed using commercial kits; OptEIA™ (E-bioscience,
San Jose, CA, USA) for IL-10, IL-12, TGF-b,I F N - g and
Quantikine
® (R&D Systems Inc., Minneapolis, MN,
USA) for VEGF.
Statistical Analysis
Statistical significance was determined using student’s
T-test. A value of p < 0.05 was considered significant.
Results
Therapeutic-DC Generation from the Autologous HSCs
Therapeutic-DC culture started with purified CD34
+
HSCs from patient’s own PBMC. Magnetic bead purified
cells were mixture of CD34
+ HSCs (63.03 ± 11.35%) and
CD14
+ monocytes (21.10 ± 5.38%) (data not shown).
Following culture of purified cells with GM-CSF and
IFN-g, cells become proliferated and differentiated into
DCs as observed with microscopes (inverted as well as
electron microscope: Figure 2A). On day 14 after cul-
ture, cells were expanded about 3000% of initiating
HSCs with DC phenotype including CD11c
++, CD40
+++,
CD54
++,C D 8 0
+,C D 8 6
+,H L Ac l a s sI
++ and HLA class
II
++. The maturation state of the cultured DCs was con-
firmed by the expression of CD83
++ with disappearing
CD1a expression (Figure 2B). Reduction of CD14
expression in the day 14 cultured cells (from 21.10 ±
5.38% to 1.97 ± 0.29%) also verified the DC differentia-
tion (data not shown). Day 14 cultured DC produced
higher amount of IL-12 than IL-10 which allow to
expecting the induction of stronger Th1 cellular immu-
nity desirable for cancer vaccine (Figure 2C).
Anti-tumor Response to Therapeutic DC with IL-2
Combination Therapy
Six patients with renal cell carcinoma and four patients
with breast cancer were treated with 5 × 10
7 DCs and
14 consecutive IL-2 injections in a single vaccination
protocol, and all patients received two vaccinations at a
one-month interval (Figure 1). No adverse effects inhi-
biting the vaccination were observed. By completion of
treatment, one case of renal cell carcinoma showed
stable disease and 9 cases showed progression of disease
(Table 2).
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Page 4 of 10Figure 2 Therapeutic-DC Generation from the Autologous HSCs. DCs were differentiated from the patient’s CD34
+ hematopoietic stem cells
as described in materials and methods. (A) Differentiated cells on day 14 have many dendrites on the surface. Scant intracellular organelles are
observed by Wright Giemsa stain × 1000, Transmission electronic microscope (TEM) and Scanning electron microscope (SEM) × 2200. (B)
Phenotype alterations of day 14 cultured cells were analyzed by flow cytometry (Green line: control, Blue solid line: cultured cells). The cultured
cells expressed mature myeloid-DC markers including CD11c and CD83. (C) Cytokines secreted into the culture supernatant (day 7 and day 14
after HSC culture setting) were measured by ELISA. Amount of cytokines were expressed as pg/10
6 cultured cells. Stars indicate the statistical
significance comparing day 7 vs. day 14 cytokine secretion by p < 0.05.
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To determine the influence of DC vaccination on NK
activity in the patients, peripheral blood lymphocytes
were collected before (w0), during (w4) and after vacci-
nation (w8). NK activity of six patients (R-M-1, R-G-2,
R-H-4, R-N-5, B-S-1 and B-H-2) increased after the 2
nd
vaccination at w8 observation (Figure 3A). In these
patients, slight modulation or maintenance of cytotoxic
NK cell proportion (CD16
+CD56
dim)w a so b s e r v e d .A
correlation between the proportion and activity of cyto-
toxic NK cells was observed in only two patients (R-H-
4, B-H-2) (Figure 3B). And reduction of cytotoxic NK
cell proportion was observed in one patient with
increased NK activity (R-G-2).
Antigen-Specific Lymphocyte Proliferation
A proliferation assay was performed with peripheral
blood lymphocytes taken from the patients before and
after the 2
nd vaccination cycle. Cells were stimulated
in vitro with KLH, which was pulsed into the thera-
peutic DCs as a surrogate antigen. In two patients (R-
M-1, R-G-2), the proliferative response was signifi-
cantly increased (P < 0.001) after vaccination (Figure
4) and the proportion of CD4
+CD25
+ cell was
reduced, concomitantly (from 12.47% to 1.7% and
from 10.0% to 1.59% for R-M-1 and R-G-2, respec-
tively; Table 3).
IFN-g Secreting T Cells
Frequency of T cells producing IFN-g that is possible
anti-tumor effector was measured by ELISPOT assay
with in vitro stimulation of KLH. Two (R-G-2, R-K-3)
out of ten patients showed significant induction (P <
0.05) of IFN-g-secreting T cells specific to KLH after
vaccination (Figure 5). Patient R-G-2 whose disease sta-
bilized in response to vaccination had the highest induc-
tion of effect cells specific to KLH. Seven patients whose
disease progressed showed no changes (R-M-1, R-N-5)
Table 2 Response to DC vaccination and results of immune monitoring
Pt. # DC dose Total No.
vaccines
Response Adverse effects Proliferation assay NK activity IFN-r ELISPOT CD4+25+cell proportion
R-M-1 5 × 10
7 2P D N o ↑↑ ↑ - ↓
R-G-2 5 × 10
7 2S D N o ↑↑ ↑ ↑ ↓
R-K-3 5 × 10
7 3P D N o - - ↑↑
R-H-4 5 × 10
7 2P D N o - ↑ --
R-N-5 5 × 10
7 2P D N o - ↑ --
R-L-6 5 × 10
7 2P D N o - - ↓ -
B-S-1 5 × 10
7 2P D N o ↑↑ ↓ ↑
B-H-2 5 × 10
7 2P D N o ↑↑ - ↑
B-L-3 5 × 10
7 2P D N o ↑ - ↓↑
B-Y-4 5 × 10
7 2P D N o - ↓ --
↑↑: Highly significant (p < 0.001) increased ↑: Significant (p < 0.05) increased
↓: Significant (p < 0.05) decreased -: No significant change
Figure 3 NK Activity and Cytotoxic NK Cell Proportion.( A )N K
activity was measured as described in materials and methods using
PBMC (effector) obtained at day 0 (baseline), during (4W) and after
the vaccination (8W). Stars indicate the statistical significance
comparing day 0 vs. after the vaccination by p < 0.05. (B) Alteration
of NK cell (0W: White bar) and after the vaccination (8W: Black bar)
was measured by flow cytometry. Numbers indicate the CD16-FITC
+
and CD56-PE
dim cytotoxic NK cell proportion.
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ing T cell numbers after DC vaccination.
Cytokine Responses
T h ep l a s m ac o n c e n t r a t i o n so fI L - 1 0a n dV E G Fd i dn o t
change significantly (data not shown). As an effector
cytokine, induction of IFN-g level was expected by DC
vaccination. However, plasma level of IFN-g was too low
to conclude the relativity to vaccine treatment (Figure
6A). Although the alterations are not statistically signifi-
cant, level of TGF-b, an immune suppressive cytokine,
had a tendency to decrease in patients R-G-2 and R-N-5
after the treatment (from 1028 pg/ml to 847 pg/ml for
R-G-2, from 995 pg/ml to 781 pg/ml for R-N-5, respec-
tively) (Figure 6B). The remaining patients showed
slightly decreased or not altered TGF-b concentration
by vaccination. In two patients (R-M-1, R-G-2), IL-12, a
stimulator of Th1 cell-mediated immune responses, was
increased by vaccination (from 245.7 pg/ml to 405.8 pg/
ml for R-M-1, from 530 pg/ml to 691 pg/ml for R-G-2,
respectively) (Figure 6C). Only one patient responded
with stabilized disease (R-G-2) showing elevation of IL-
12 accompanied by reduction of TGF-b secretion.
Discussion
In the present study, cancer vaccine-related safety and
the immune alteration was reported. The study was
phase I/II clinical trial of cancer vaccine composed with
autologous HSC-derived DC and IL-2 performed on six
RCC and four breast cancer patients. The vaccine was
tolerable and induced the antigen-specific immune
alterations. (Table 2)
Using DC vaccine as an anti-cancer therapy module
has been facilitated by the development of methods to
generate DCs from proliferating CD34
+ precursors or
from non-proliferating CD14
+ monocytes. In our study,
CD34
+ cells cultured with GM-CSF and IFN-g were
expanded and differentiated into the cells with DC char-
acters by about 3000% of initiating HSCs. Cultured-cells
secreted IL-12, Th1-response inducing cytokine, more
than IL-10 indicates that cultured DCs are possible as a
therapeutic-DC (Figure 2).
A number of clinical studies have been carried out
since 1994, applying tumor antigen loaded DC based
Figure 4 Antigen-Specific Lymphocyte Proliferation. The proliferative response was determined by
3H-thymidine incorporation (DPM). Data
plotted as the relative change from pre-vaccination baseline. Stars are indicated the statistical significance (*p < 0.05; **p < 0.001) comparing pre
(White bar) vs. post-vaccination (Black bar).
Table 3 Percentage of CD4
+25
+ T cell Subset
Pt. # Pre(0w) Post(8w)
R-M-1 12.47% 1.70%
R-G-2 10.00% 1.59%
R-K-3 1.02% 1.88%
R-H-4 4.40% 5.83%
R-N-5 4.74% 6.20%
R-L-6 2.70% 3.59%
B-S-1 3.31% 5.94%
B-H-2 4.54% 9.29%
B-L-3 3.66% 7.05%
B-Y-4 8.18% 6.08%
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responses coincided with the induction of specific T-
cell responses. Thus, to evaluate efficacy of DC vaccine
induction of tumor-specific T cells and the relationship
to the clinical response has been demonstrated [6-9].
After vaccination, KLH-specif i cl y m p h o c y t ep r o l i f e r a -
tion was induced in 8 out of 10 patients. However,
among KLH-specifically activated immune cells, IFN-g
secreting effector T cell frequency was elevated in only
2 RCC patients (Figure 5). And in one patient of RCC
with stable disease, the elevation correlated with clini-
cal outcome. The value of ELISPOT assay measuring
effector T cell frequency as a predictor of DC vaccine-
related anti-tumor responses was also indicated in
other group [23].
In our trial, low-dose IL-2 was injected following DC
injection expecting positive influence on the induction
of cellular immunity including NK activity. Six out of
ten patients showed increasing NK activity after vacci-
nation and in only two patients the increased propor-
tion of CD16
+CD56
dim cytotoxic-NK cell was
accompanied by increased activity. However, no rele-
vance to clinical results was observed (Figure 3). As a
T cell growth factor, IL-2 was known to induce not
only effector T cells but also CD4
+CD25
+ regulatory T
cells [19-21]. Although we used low-dose IL-2,
increased CD4
+CD25
+ T cell subset proportion was
observed in 7 out of 10 patients. Interestingly, the
most significant induction of KLH-specific lymphocyte
proliferation was indicated in the two patients showing
CD4
+CD25
+ T cell subset reduction and clinical
response was achieved in this one out of two patients
(Figure 4).
High blood levels of TGF-b have been suggested as an
indicator of poor prognosis in advanced cancer patients
[8,24]. Even though the statistical significant was not
observed, in the RCC patient with stabilized disease,
reducing phenomenon of TGF-b level was detected after
the vaccination. In the same patient, the level of IL-12
was increased by vaccination (Figure 6). Our result
could be related to a published report showing associa-
tion of increased IL-12 level with anti-tumor efficacy in
RCC patients receiving immunotherapy [25]. The data
suggest that the concomitant alterations of immune
inhibitory cytokine (TGF-b) and immune stimulatory
cytokine (IL-12) may represent the DC vaccine-induced
clinical response.
Conclusion
Our anti-tumor vaccine with DC and IL-2 was tolerable
and induced the antigen-specific cellular immunity in
the metastatic RCC and Breast cancer patients. Only the
patient with objective clinical response revealed the sig-
nificant induction of anti-tumor immunity such as IFN-
g producing CD8
+ cell proportion and IL-12 secretion at
the same time with the reduction of inhibitory immune
responses including CD4
+CD25
+ Tc e l ls u b s e t sw h i c h
possibly represent the regulatory T cells and TGF-b
Figure 5 IFN-g Secreting T Cells was measured by ELISPOT assay. ELISPOT assay counting IFN-g secreting T cells was performed on before
(Pre: White bar) and after the vaccination (Post: Black bar). PBMCs were incubated with KLH for 20 h at 37°C to induce the Ag-specific IFN-g
secretion. Stars are indicated the statistical significance (*p < 0.05) comparing before vs. after vaccination.
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Page 8 of 10secretion. Data suggest that in DC vaccine trial, the
objective clinical responses may anticipate when the
anti-tumor immunity is stimulated concomitantly with
inhibition of regulatory immunity.
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